It would be tough (but not impossible) to get hypoglycemia benefit on label, <50% chance IMO, the best NVO could hope for is to put data on label without definite claim. Instead, NVO can use degludec's flexible dosing schedule due to its ultra-long half life (24-25 hrs), and combinations with NovoLog, Victoza as major selling point against Lantus. That's NVO's advantage as a fully integrated diabetes specialty pharma.
Here is summary of degludec's benefit during advisory meeting:
Market Data 
Markets 
AI
